Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Immunocytochemistry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ALX-804-296-C100 - Provider product page
- Provider
- Enzo Life Sciences
- Proper citation
- Enzo Life Sciences Cat#ALX-804-296-C100, RRID:AB_2052719
- Product name
- TRAIL (human) monoclonal antibody (2E5)
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Description
- Protein A-affinity purified. Sterile filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 2E5
- Vial size
- 100 μg
- Storage
- -20°C
- Handling
- Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20¡C.
Submitted references Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
Oh YT, Deng J, Yue P, Owonikoko TK, Khuri FR, Sun SY
Oncogene 2016 Jan 28;35(4):459-67
Oncogene 2016 Jan 28;35(4):459-67
IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, Pilla L, Martinelli G, Pizzolo G, Rivoltini L, Cassatella MA
Blood 2004 May 15;103(10):3837-44
Blood 2004 May 15;103(10):3837-44
TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T
Leukemia 2002 Jan;16(1):67-73
Leukemia 2002 Jan;16(1):67-73
No comments: Submit comment
Supportive validation
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Apoptosis induced in Jurkat T leukemia cells by KillerTRAILTM (Prod. No. ALX-201-073) is completely blocked by mouse MAb to TRAIL (human) (2E5)Ê(Prod. No. ALX-804-296) in a concentration range of 0.5-1.5µg/ml. Concentration of MAb 2E5 required for inhibition may vary depending of the cell type studied and the concentration of soluble recombinant human TRAIL used. The neutralizing activity of MAb 2E5 has been confirmed with various sources of soluble recombinant human TRAIL including KillerTRAILTM. Method: Jurkat cells (5x104) were treated with KillerTRAILTM (300ng/ml) in the presence or absence of the MAb to TRAIL (human) (2E5) or a control IgG1 mouse monoclonal antibody. After 16 hours apoptosis was evaluated by forward/sideward scatter (FSC/SSC) combined with propidium iodide (PI) staining analyzed by flow cytometry.
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Ê MAb to TRAIL (human) (2E5) (Prod. No. ALX-804-296) can be used to detect surface human TRAIL in transiently transfected 293T cells in flow cytometry as well on untransfected cells expressing endogenous surface TRAIL. Method: 293T cells (10cm dishes) were transfeced with 0, 1, or 15µg plasmid coding for full length human TRAIL for 24 hours using a standard calcium phosphate transfection method. All dishes were cotransfected with 1µg plasmid coding for EGFPas a cotransfection marker. Viable cells (FSC/SSC region R1), that were GFP-positive (transfected) (FL1 region R3) were analyzed with respect to surface expression of human TRAIL. Cells were stained with MAb to TRAIL (human) (2E5) as well as with an isotype-matched control (control IgG1) at 10µg/ml.Ê Binding of the primary MAbs is detected using RPE conjugated goat anti-mouse IgG (FL2).
- Submitted by
- Enzo Life Sciences (provider)
- Main image
- Experimental details
- Neutralizing effect of MAb to TRAIL (human) (2E5) on TRAIL-induced apoptosis (TRAIL, Soluble (human) (recombinant) Set (Prod. No. ALX-850-018); containing Enhancer for Ligands).